Cardiology

Back to articles

Omapatrilat: Balancing Risks, Benefits in Severe Congestive Heart Failure

KEY POINT

Evidence is growing that vasopeptidase inhibition—as provided by the investigational agent omapatrilat (Vanlev—Bristol-Myers Squibb)—adds an important element in treatment of patients with congestive heart failure (CHF). But the possibility that the new drug causes angioedema continues to prevent the manufacturer from seeking FDA approval in the United States.

SOURCES

McLean DR et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:479–86.

Rouleau JL et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356:615–20.

Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema [editorial]. Lancet. 2000;356:608–9.